Clinical Trial: A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07448038) titled 'A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events' on Feb. 25.

Brief Summary: The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Atherosclerosis

Intervention: DRUG: Selnoflast

Selnoflast will be administered...